Therapy-induced Ph1 suppression in chronic myeloid leukemia: Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion

F. Lo Coco, F. Mandelli, D. Diverio, G. Alimena, P. De Fabritiis, G. Meloni, M. Cedrone, M. Frontani, A. Guerrasio, G. Saglio

Research output: Contribution to journalArticle

Abstract

In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b inferferon (IFN) treatment, whereas 18 underwent autografting in an early phase of the disease. In each case bone marrow samples were examined pre-treatment and at +2, +6 and +12 months in order to verify the degree of Ph1 suppression. In addition, the position of the breakpoint within the BCR region was mapped with multiple restriction enzymes. In 17 cases (59%) a significant Ph1 reduction was observed at +60 days (0-57% residual Ph1+ cells). In three of these cases, a complete cytogenetic response was confirmed at the DNA level by Southern blotting, but specific amplification of the BCR/ABL junction by the polymerase chain reaction (PCR), performed in two cases, still showed residual disease. The remaining 12 patients (41%) revealed a substantial persistence of Ph1+ metaphases (90-100%). Nine of 17 responding patients (53%) showed an increase of Ph1+ cells at 6 months, and five of 20 evaluated had a further increase at 12 months. With the exception of the results seen by PCR, comparison of molecular and cytogenetic techniques did not show significant differences. The variable degrees of Ph1 suppression observed did not appear to be associated with the position of BCR breakpoints. The factors predicting cytogenetic response to IFN and stem cell autograft and long-term durability of cytoconversion should be elucidated in further studies and with longer follow-up.

Original languageEnglish
Pages (from-to)253-258
Number of pages6
JournalBone Marrow Transplantation
Volume6
Issue number4
Publication statusPublished - 1990

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Stem Cells
Cytogenetic Analysis
Drug Therapy
Polymerase Chain Reaction
Autologous Transplantation
Autografts
Metaphase
Southern Blotting
Therapeutics
Bone Marrow
DNA
Enzymes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Therapy-induced Ph1 suppression in chronic myeloid leukemia : Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. / Lo Coco, F.; Mandelli, F.; Diverio, D.; Alimena, G.; De Fabritiis, P.; Meloni, G.; Cedrone, M.; Frontani, M.; Guerrasio, A.; Saglio, G.

In: Bone Marrow Transplantation, Vol. 6, No. 4, 1990, p. 253-258.

Research output: Contribution to journalArticle

Lo Coco, F, Mandelli, F, Diverio, D, Alimena, G, De Fabritiis, P, Meloni, G, Cedrone, M, Frontani, M, Guerrasio, A & Saglio, G 1990, 'Therapy-induced Ph1 suppression in chronic myeloid leukemia: Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion', Bone Marrow Transplantation, vol. 6, no. 4, pp. 253-258.
Lo Coco, F. ; Mandelli, F. ; Diverio, D. ; Alimena, G. ; De Fabritiis, P. ; Meloni, G. ; Cedrone, M. ; Frontani, M. ; Guerrasio, A. ; Saglio, G. / Therapy-induced Ph1 suppression in chronic myeloid leukemia : Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. In: Bone Marrow Transplantation. 1990 ; Vol. 6, No. 4. pp. 253-258.
@article{b5c1a50bf92343c5814e1c917b0526e0,
title = "Therapy-induced Ph1 suppression in chronic myeloid leukemia: Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion",
abstract = "In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b inferferon (IFN) treatment, whereas 18 underwent autografting in an early phase of the disease. In each case bone marrow samples were examined pre-treatment and at +2, +6 and +12 months in order to verify the degree of Ph1 suppression. In addition, the position of the breakpoint within the BCR region was mapped with multiple restriction enzymes. In 17 cases (59{\%}) a significant Ph1 reduction was observed at +60 days (0-57{\%} residual Ph1+ cells). In three of these cases, a complete cytogenetic response was confirmed at the DNA level by Southern blotting, but specific amplification of the BCR/ABL junction by the polymerase chain reaction (PCR), performed in two cases, still showed residual disease. The remaining 12 patients (41{\%}) revealed a substantial persistence of Ph1+ metaphases (90-100{\%}). Nine of 17 responding patients (53{\%}) showed an increase of Ph1+ cells at 6 months, and five of 20 evaluated had a further increase at 12 months. With the exception of the results seen by PCR, comparison of molecular and cytogenetic techniques did not show significant differences. The variable degrees of Ph1 suppression observed did not appear to be associated with the position of BCR breakpoints. The factors predicting cytogenetic response to IFN and stem cell autograft and long-term durability of cytoconversion should be elucidated in further studies and with longer follow-up.",
author = "{Lo Coco}, F. and F. Mandelli and D. Diverio and G. Alimena and {De Fabritiis}, P. and G. Meloni and M. Cedrone and M. Frontani and A. Guerrasio and G. Saglio",
year = "1990",
language = "English",
volume = "6",
pages = "253--258",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Therapy-induced Ph1 suppression in chronic myeloid leukemia

T2 - Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion

AU - Lo Coco, F.

AU - Mandelli, F.

AU - Diverio, D.

AU - Alimena, G.

AU - De Fabritiis, P.

AU - Meloni, G.

AU - Cedrone, M.

AU - Frontani, M.

AU - Guerrasio, A.

AU - Saglio, G.

PY - 1990

Y1 - 1990

N2 - In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b inferferon (IFN) treatment, whereas 18 underwent autografting in an early phase of the disease. In each case bone marrow samples were examined pre-treatment and at +2, +6 and +12 months in order to verify the degree of Ph1 suppression. In addition, the position of the breakpoint within the BCR region was mapped with multiple restriction enzymes. In 17 cases (59%) a significant Ph1 reduction was observed at +60 days (0-57% residual Ph1+ cells). In three of these cases, a complete cytogenetic response was confirmed at the DNA level by Southern blotting, but specific amplification of the BCR/ABL junction by the polymerase chain reaction (PCR), performed in two cases, still showed residual disease. The remaining 12 patients (41%) revealed a substantial persistence of Ph1+ metaphases (90-100%). Nine of 17 responding patients (53%) showed an increase of Ph1+ cells at 6 months, and five of 20 evaluated had a further increase at 12 months. With the exception of the results seen by PCR, comparison of molecular and cytogenetic techniques did not show significant differences. The variable degrees of Ph1 suppression observed did not appear to be associated with the position of BCR breakpoints. The factors predicting cytogenetic response to IFN and stem cell autograft and long-term durability of cytoconversion should be elucidated in further studies and with longer follow-up.

AB - In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b inferferon (IFN) treatment, whereas 18 underwent autografting in an early phase of the disease. In each case bone marrow samples were examined pre-treatment and at +2, +6 and +12 months in order to verify the degree of Ph1 suppression. In addition, the position of the breakpoint within the BCR region was mapped with multiple restriction enzymes. In 17 cases (59%) a significant Ph1 reduction was observed at +60 days (0-57% residual Ph1+ cells). In three of these cases, a complete cytogenetic response was confirmed at the DNA level by Southern blotting, but specific amplification of the BCR/ABL junction by the polymerase chain reaction (PCR), performed in two cases, still showed residual disease. The remaining 12 patients (41%) revealed a substantial persistence of Ph1+ metaphases (90-100%). Nine of 17 responding patients (53%) showed an increase of Ph1+ cells at 6 months, and five of 20 evaluated had a further increase at 12 months. With the exception of the results seen by PCR, comparison of molecular and cytogenetic techniques did not show significant differences. The variable degrees of Ph1 suppression observed did not appear to be associated with the position of BCR breakpoints. The factors predicting cytogenetic response to IFN and stem cell autograft and long-term durability of cytoconversion should be elucidated in further studies and with longer follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0025197376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025197376&partnerID=8YFLogxK

M3 - Article

C2 - 2085700

AN - SCOPUS:0025197376

VL - 6

SP - 253

EP - 258

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -